Abstract: ?-RgIA4 peptide analogs, compositions therewith, and methods for their treatment and use are disclosed and described. For example, an ?-RgIA4 peptide analog can comprise a recognition finger region configured to bind to an ?9?10 nicotinic acetylcholine receptor, and a side chain bonding configuration that protects an inter-cysteine sulfur linkage.

Abstract: Described are oligonucleotides (LAMP primers), compositions, kits, and method for loop-mediated-isothermal amplification (LAMP) and/or detection of SARS-CoV-related betacoronaviruses. The methods can be used to in diagnosing SARS-CoV-2 infection.

Abstract: STAT3 (Signal Transducer and Activator of Transcription), which is overactive in two-thirds of human cancers, is shown herein to inhibit HR repair. This newly identified linkage of STAT3 to HR impairment forecasts that many more cancers, beyond just breast and ovarian cancers, are likely to be susceptible to PARP inhibitors and other synthetic lethal therapies. Also disclosed herein is a gene signature that can predict which cancers are likely to respond to therapy with PARP inhibitors and other synthetic lethal therapies.

Abstract: Described are methods for generating human antibodies capable of blocking one or more functions of coronavirus viroporins. The methods can be used to generate therapeutic antibodies to treat or prevent coronavirus infection, including SARS-CoV-2 infection.

Abstract: The present invention relates to synthetic analgesic peptides that are analogs of the ?-conotoxin peptide RgIA and their use for treating pain and other disorders.

Abstract: The present disclosure describes analog conotoxin peptides of the ?-contoxin peptide RgIA. These analog conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, inflammatory conditions, inflammation, and/or cancer.

Abstract: The invention belongs to the field of biochemistry and molecular biology. The present invention provides a mutant of ?-conotoxin peptide TxID, a pharmaceutical composition and use thereof. The TxID mutant is capable of specifically blocking acetylcholine receptors (nAChRs), in particular, ?3?4, or ?6/?3?4 subtype, and has application prospects in the manufacture of a medicament for smoking cessation and detoxification and analgesia, a medicament for treating psychiatric diseases and cancers, regulating appetite, and a tool medicine for neuroscience.

Abstract: An educational system presents an interactive avatar representing a subject matter expert in a particular field on a student's device, where the avatar can respond to queries posed by the student, and accompany the response with additional supporting information. The avatar's responses are based on artificial intelligence comparisons between the student queries and a knowledge base of anticipated questions, responses and learning goals. An authoring manager system employs natural language processing to identify an underlying meaning in the student's query and to add semantically equivalent questions in the knowledge base and internet searches to aid in compiling the list of anticipated questions. A student profile is stored containing student information and a history of the student's interaction with the avatar. Learning manager software, using the learning goals in the knowledge base and a record of the conversation, can compare and assess the student's progress to the learning goals.

Abstract: Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.

Abstract: The present invention relates to wedge coupler lug brackets for attachment to an implement to permit connection of a wedge coupler on the work arm of a primary mover such as a back hoe, excavator or loader. The wedge hook brackets comprising a pair of lugs each lug having a rear facing hook section, a saddle section, the rear facing hook section and saddle section configured and adapted to accommodate bosses on the wedge coupler on the work arm that transfer the digging force from a powerlink of the primary mover to the attachment and wedge bar receiver sections to receive a wedge bar on the wedge coupler. The wedge bar receiver section is configured and adapted, in combination with the rear facing hook section, to retain the attachment to the wedge coupler by engagement with both lugs across the width of the pair of wedge coupler lug brackets mounted on the attachment.

Abstract: The present invention relates to the use of compounds that block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the ?9?10 subtype of the nAChR.

Abstract: The present invention pertains to fields of biochemistry and molecular biology, relates to an ?O-superfamily conotoxin peptide, pharmaceutical composition thereof, preparation method and use thereof. The present invention further relates to a propeptide of the conotoxin peptide, nucleic acid construct thereof, expression vector and transformed cell thereof, and fusion protein thereof. The present invention further relates to a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The new ?O-superfamily conotoxin peptide of the present invention is capable of specifically blocking acetylcholine receptor (nAChRs) (e.g., ?9?10 nAChR), and NMDA receptor (e.g.

Abstract: An educational system presents an interactive avatar representing a subject matter expert in a particular field on a student's device, where the avatar can respond to queries posed by the student, and accompany the response with additional supporting information. The avatar's responses are based on artificial intelligence comparisons between the student queries and a knowledge base of anticipated questions, responses and learning goals. An authoring manager system employs natural language processing to identify an underlying meaning in the student's query and to add semantically equivalent questions in the knowledge base and internet searches to aid in compiling the list of anticipated questions. A student profile is stored containing student information and a history of the student's interaction with the avatar. Learning manager software, using the learning goals in the knowledge base and a record of the conversation, can compare and assess the student's progress to the learning goals.

Abstract: Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.

Abstract: Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.

Abstract: The present invention provides a novel ?-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide. The present invention discloses a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The ?-conotoxin peptide of the present invention can specifically block acetylcholine receptor (nAChRs, such as ?3?2 nAChRs, ?6/?3?2?3 nAChR or ?3?4 nAChR or ?6/?3?4 nAChR), has activity for treatment of neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, cancers, and can be used in the manufacture of a medicament for analgesia and smoking cessation and drug-withdrawal, a medicament for treatment of mental diseases and cancers, as well as a tool drug for neurosciences.

Abstract: Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.

Abstract: The present disclosure describes analog conotoxin peptides of the ?-contoxin peptide RgIA. These analog conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, inflammatory conditions, inflammation, and/or cancer.

Abstract: A sending entity creates a structured document and communicates it to a receiving entity includes a transform to ensure document elements are not moved during communication. The structured document comprises a root element and a set of child elements. A child element is protected by a digital signature, prior to being positioned within the document. This element includes a sending entity security policy. The receiving entity includes a transform that determines whether the signed element is in a given position within the received document. The transform evaluates the data string against a set of ancestor elements of the signed element to determine whether the signed element is in the given position. If so, the transform preferably outputs the signed element itself. If the transform determines that the signed element has been moved, however, preferably it outputs a given value other than the signed element.

Abstract: The present invention relates conotoxin peptides that are analogs of the ?-conotoxin peptide RgIA. These conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, such as neuropathic pain and inflammatory pain, inflammatory disorders, such as rheumatic diseases, and in the treatment of breast cancer.